A Dose-Tailored Anti-Plasma Cell Regimen Lowers the Mortality of Late-Stage Cardiac Amyloidosis

Abstract

A major obstacle to using current guideline-recommended chemotherapy in patients with advanced light-chain cardiac amyloidosis (LCCA) is their intolerance to standard drug dosages. The study aimed to assess the efficacy and safety of the dose-tailored BD and DBD regimen proposed by our team for patients with LCCA at Mayo Stage III. A total of 119 patients who met the inclusion and exclusion criteria for cardiac amyloidosis were recruited and divided into three groups: group A, group B, and group C who received supportive therapy, dose-tailored BD regimen, and dose-tailored DBD regimen, respectively. Survival rate and time, hematologic and cardiac response, and adverse events were evaluated during a median follow-up of 30.2 months. No significant differences in baseline characteristics were found among the three groups. Group B and C showed increased survival rates and time compared to group A. Group C showed improved hematologic and cardiac responses relative to group B. Additionally, group C showed fewer adverse events related to chemotherapy compared to group B. Both dose-tailored BD and DBD regimens increased survival rates and time in advanced LCCA patients, with the dose-tailored DBD regimen demonstrating superior efficacy and safety. Further randomized clinical trials are needed to confirm these preliminary findings.

Keywords

cardiac amyloidosis / cardiac response / dose-tailored anti-plasma cell regimen / heart failure / hematologic response

References

[1] S. Ash, E. Shorer, D. Ramgobin, et al., “Cardiac Amyloidosis - A Review of Current Literature for the Practicing Physician,” Clinical Cardiology 44 (2021): 322-331.

[2] M. Skinner, J. Anderson, R. Simms, et al., “Treatment of 100 Patients With Primary Amyloidosis: A Randomized Trial of Melphalan, Prednisone, and Colchicine Versus Colchicine Only,” American Journal of Medicine 100 (1996): 290-298.

[3] A. D. Wechalekar, M. Fontana, C. C. Quarta, and M. Liedtke, “AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review,” JACC: CardioOncology 4 (2022): 427-441.

[4] G. Palladini, F. Lavatelli, P. Russo, et al., “Circulating Amyloidogenic Free Light Chains and Serum N-Terminal Natriuretic Peptide Type B Decrease Simultaneously in Association With Improvement of Survival in AL,” Blood 107 (2006): 3854-3858.

[5] A. D. Wechalekar, S. O. Schonland, E. Kastritis, et al., “A European Collaborative Study of Treatment Outcomes in 346 Patients With Cardiac Stage III AL Amyloidosis,” Blood 121 (2013): 3420-3427.

[6] A. D. Wechalekar, J. D. Gillmore, J. Bird, et al., “Guidelines on the Management of AL Amyloidosis,” British Journal of Haematology 168 (2015): 186-206.

[7] A. Dispenzieri, F. Buadi, S. K. Kumar, et al., “Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement,” Mayo Clinic Proceedings 90 (2015): 1054-1081.

[8] V. Sanchorawala, M. Boccadoro, M. Gertz, et al., “Guidelines for High Dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis: EHA-ISA Working Group Guidelines,” Amyloid 29 (2022): 1-7.

[9] S. K. Kumar, N. S. Callander, K. Adekola, et al., “Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network: JNCCN 21 (2023): 67-81.

[10] K. Shen, Z. Tian, Y. Gao, et al., “Chinese Consensus on the Diagnosis and Treatment of Immunoglobulin Light-Chain Cardiac Amyloidosis,” Chinese Medical Journal 137 (2024): 127-129.

[11] P. G. Richardson, P. Sonneveld, M. W. Schuster, et al., “Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma,” New England Journal of Medicine 352 (2005): 2487-2498.

[12] B. G. M. Durie, A. Hoering, M. H. Abidi, et al., “Bortezomib With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Patients With Newly Diagnosed Myeloma Without Intent for Immediate Autologous Stem-Cell Transplant (SWOG S0777): A Randomised, Open-Label, Phase 3 Trial,” Lancet 389 (2017): 519-527.

[13] K. N. Shen, Y. J. Gao, L. Chang, et al., “Efficacy and Safety of Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Mayo 2004 Stage IIIA or IIIB Light-Chain Amyloidosis: A Prospective Phase II Study,” Haematologica 109 (2024): 2355-2358.

[14] S. Lonial, B. M. Weiss, S. Z. Usmani, et al., “Daratumumab Monotherapy in Patients With Treatment-Refractory Multiple Myeloma (SIRIUS): An Open-Label, Randomised, Phase 2 Trial,” Lancet 387 (2016): 1551-1560.

[15] M. A. Alrasheed, K. A. Alamer, M. Albishi, et al., “Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases From 2015 to 2022,” Pharmaceuticals (Basel) 17 (2024): 815.

[16] P. Phull, V. Sanchorawala, D. Brauneis, et al., “High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in Patients With AL Amyloidosis and Cardiac Defibrillators,” Bone Marrow Transplantation 54 (2019): 1304-1309.

[17] E. Kastritis, G. Palladini, M. C. Minnema, et al., “Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis,” New England Journal of Medicine 385 (2021): 46-58.

[18] A. D. Wechalekar and V. Sanchorawala, “Daratumumab in AL Amyloidosis,” Blood 140 (2022): 2317-2322.

[19] C. Sun, X. Wang, R. Zhang, et al., “Efficacy and Safety of Intravenous Daratumumab-Based Treatments for AL Amyloidosis: A Systematic Review and Meta-Analysis,” Cancer Cell International 22 (2022): 222.

[20] G. P. Kaufman, S. L. Schrier, R. A. Lafayette, et al., “Daratumumab Yields Rapid and Deep Hematologic Responses in Patients With Heavily Pretreated AL Amyloidosis,” Blood 130 (2017): 900-902.

[21] M. Grogan, A. Dispenzieri, and M. A. Gertz, “Light-Chain Cardiac Amyloidosis: Strategies to Promote Early Diagnosis and Cardiac Response,” Heart 103 (2017): 1065-1072.

[22] E. Muchtar, A. Dispenzieri, M. A. Gertz, et al., “Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update,” Mayo Clinic Proceedings 96 (2021): 1546-1577.

[23] W. Lamm, W. Willenbacher, A. Lang, et al., “Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis,” Annal of Hematology 90 (2011): 201-206.

[24] V. Sanchorawala, S. Sarosiek, A. Schulman, et al., “Safety, Tolerability, and Response Rates of Daratumumab in Relapsed AL Amyloidosis: Results of a Phase 2 Study,” Blood 135 (2020): 1541-1547.

[25] A. Dispenzieri, M. A. Gertz, R. A. Kyle, et al., “Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis,” Journal of Clinical Oncology 22 (2004): 3751-3757.

[26] B. R. Dey, S. S. Chung, T. R. Spitzer, et al., “Cardiac Transplantation Followed by Dose-Intensive Melphalan and Autologous Stem-Cell Transplantation for Light Chain Amyloidosis and Heart Failure,” Transplantation 90 (2010): 905-911.

[27] X. Brennan, B. Withers, A. Jabbour, et al., “Efficacy of Bortezomib, Cyclophosphamide and Dexamethasone in Cardiac AL Amyloidosis,” Internal Medicine Journal 52 (2022): 1826-1830.

[28] T. Shragai, M. Gatt, N. Lavie, et al., “Daratumumab for Relapsed AL Amyloidosis - When Cumulative Real-World Data Precedes Clinical Trials: A Multisite Study and Systematic Literature Review,” European Journal of Haematology 106 (2021): 184-195.

[29] C. Mitchell, P. S. Rahko, L. A. Blauwet, et al., “Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations From the American Society of Echocardiography,” Journal of the American Society of Echocardiography 32 (2019): 1-64.

[30] S. Oubari, U. Hegenbart, R. Schoder, et al., “Daratumumab in First-Line Treatment of Patients With Light Chain Amyloidosis and Mayo Stage IIIb Improves Treatment Response and Overall Survival,” Haematologica 109 (2024): 220-230.

[31] A. Freites-Martinez, N. Santana, S. Arias-Santiago, and A. Viera, “Using the Common Terminology Criteria for Adverse Events (CTCAE—Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies,” Actas Dermo-Sifiliográficas (English Edition) 112 (2021): 90-92.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.